MedTrace Logo

The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence

NCT05387148 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-06-03

No results posted yet for this study

Summary

The study will explore the psychophysiological and neurobiological and mechanisms of CBD in participants with alcohol use disorder

Conditions

  • Alcohol Use Disorder (AUD)

Interventions

DRUG

Cannabidiol (CBD)

Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.

DRUG

Placebo

The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.

Sponsors & Collaborators

  • University of Sydney

    collaborator OTHER

  • Lambert Initiative for Cannabinoid Therapeutics

    collaborator UNKNOWN

  • South West Sydney Local Health District

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2023-06-30
Completion
2024-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05387148 on ClinicalTrials.gov